1. Introduction

XEOMIN (incobotulinumtoxinA) is a botulinum toxin type A product evaluated in randomized clinical studies across aesthetic and therapeutic settings. Its aesthetic evidence base includes placebo-controlled Phase III trials for moderate-to-severe glabellar frown lines and direct randomized comparisons with onabotulinumtoxinA, the active ingredient in BOTOX Cosmetic. ［1–3］

These studies address related but distinct clinical questions. Placebo-controlled trials assess whether incobotulinumtoxinA produces a treatment response beyond placebo. Active-comparator trials examine outcomes against another specified product, sometimes using an equivalence or non-inferiority framework.

The interpretation of each result depends on the exact product, population, dose, endpoint, assessment time, and statistical design. An equivalence finding in one glabellar-line trial does not establish that two botulinum toxin products are identical or universally interchangeable.

This article reviews the randomized evidence identified in the BotoxWiki BW-25 source draft and explains what its principal findings support—and what they do not.

2. What Is the Clinical Evidence Base for XEOMIN?

The randomized studies discussed here focus primarily on moderate-to-severe glabellar frown lines. The source draft identifies three principal publications: a placebo-controlled Phase III study, a 250-participant direct equivalence study, and an earlier international non-inferiority trial. ［1–3］

Table 1. What Is the Clinical Evidence Base for XEOMIN?

Evidence category

Study design

Clinical question

Placebo-controlled Phase III

IncobotulinumtoxinA vs placebo

Does the studied treatment demonstrate efficacy beyond placebo?

Direct equivalence trial

IncobotulinumtoxinA vs onabotulinumtoxinA

Are the primary outcomes within a prespecified equivalence margin?

Active-comparator non-inferiority trial

IncobotulinumtoxinA vs onabotulinumtoxinA

Is the treatment difference within the predefined non-inferiority margin?

Although these studies investigate the same general facial region, their endpoints and statistical objectives differ. Their response rates should not be combined or compared without considering those differences.

3. Placebo-Controlled Phase III Evidence in Glabellar Frown Lines

A multicenter, randomized Phase III study published in Dermatologic Surgery in 2013 evaluated a single treatment of incobotulinumtoxinA in adults with moderate-to-severe glabellar frown lines. The studied dose was 20 U. ［1］

The study assessed treatment response using investigator and patient evaluations and reported statistically significant efficacy compared with placebo.

Why placebo-controlled evidence matters

A placebo-controlled design helps establish whether the observed improvement is attributable to the studied treatment rather than to the response observed in the control group.

For glabellar lines, the definition of a responder is particularly important. A trial may use investigator-assessed severity, patient-assessed severity, or a composite definition requiring both assessments.

Consequently, an efficacy percentage from one trial cannot automatically be compared with a percentage from another trial using a different responder definition.

The Phase III evidence supports the efficacy of the evaluated 20-U incobotulinumtoxinA protocol for the studied glabellar-line population. It does not, by itself, establish comparative efficacy against another active botulinum toxin product. ［1］

4. Direct Equivalence Study: IncobotulinumtoxinA vs OnabotulinumtoxinA

Kane and colleagues published a randomized, double-blind trial in 2015 investigating the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. ［2］

The study enrolled 250 women and compared 20 U incobotulinumtoxinA with 20 U onabotulinumtoxinA. The primary assessment was conducted at one month.

The trial reported equivalence for its prespecified primary endpoint within the defined equivalence margin. ［2］

Table 2. Direct Equivalence Study: IncobotulinumtoxinA vs OnabotulinumtoxinA

Study characteristic

Reported information

Publication

Kane et al., 2015

Design

Randomized, double-blind, direct-comparison trial

Participants

250 women

Treatment area

Glabellar frown lines

Investigational treatment

IncobotulinumtoxinA, 20 U

Active comparator

OnabotulinumtoxinA, 20 U

Primary assessment

One month

Statistical framework

Equivalence

Main interpretation

Equivalence reported within the prespecified primary-endpoint margin

|

What does the equivalence result mean?

An equivalence trial is designed to determine whether the treatment difference falls within predefined bounds in both directions.

This differs from a non-inferiority trial, which generally tests whether the investigational treatment is not worse than the comparator by more than a specified margin.

The Kane study provides direct comparative evidence for the studied 20-U glabellar-line protocol. However, equivalence at the primary endpoint does not establish identical formulations, equivalent outcomes across every aesthetic indication, or universal interchangeability of potency units. ［2］

5. Earlier Non-Inferiority Evidence

An earlier international Phase III trial published by Sattler and colleagues in 2010 compared incobotulinumtoxinA with onabotulinumtoxinA for glabellar frown lines. ［3］

The study reported non-inferiority under its prespecified design.

This result contributes a separate line of active-comparator evidence to the incobotulinumtoxinA clinical program. Unlike the Kane equivalence trial, its primary statistical question was whether incobotulinumtoxinA met the defined non-inferiority criterion.

The two findings should be reported using their original statistical terminology: equivalence for the Kane trial and non-inferiority for the Sattler trial.

Neither term should be rewritten as a general superiority claim.

6. How the Randomized Studies Fit Together

The three publications provide complementary evidence.

|Table 3. How the Randomized Studies Fit Together

Study

Comparator

Principal finding

Interpretation

Phase III study, 2013

Placebo

Statistically significant efficacy reported

Supports efficacy beyond placebo in the studied protocol

Kane et al., 2015

OnabotulinumtoxinA

Equivalence reported

Applies to the prespecified endpoint, margin, dose, and time point

Sattler et al., 2010

OnabotulinumtoxinA

Non-inferiority reported

Applies to the study's predefined non-inferiority framework

7. Evidence Beyond the Glabella

Randomized aesthetic studies have also evaluated incobotulinumtoxinA in treatment approaches involving multiple upper facial-line regions.

These studies can provide information about outcomes when more than one facial region is treated. However, their results should be interpreted separately from glabellar-only trials because treatment areas, total doses, injection patterns, and endpoints may differ.

The BW-25 source draft notes this broader evidence but does not provide a specific publication or numerical results for a multi-region trial. Accordingly, no additional response percentages or comparative claims are assigned to that evidence here.

8. Does a 20-U vs 20-U Trial Establish Universal Dose Equivalence?

No.

The Kane trial evaluated 20 U incobotulinumtoxinA and 20 U onabotulinumtoxinA in a defined glabellar-line protocol. That dose selection is part of the study design. ［2］

Botulinum toxin potency units are product-specific. A numerical dose relationship investigated in one trial should not be converted into a universal rule for another indication, injection pattern, or product.

When describing comparative evidence, the precise dose used in the publication should be stated without implying that the products are interchangeable in all clinical circumstances.

9. What Can Be Concluded About Safety?

The randomized clinical program includes safety assessment, but safety conclusions must remain tied to the study population, exposure, adverse-event definitions, and follow-up period. ［1–3］

A trial designed to demonstrate equivalence or non-inferiority for an efficacy endpoint does not automatically demonstrate equivalence in every safety outcome.

Clinical use also requires reference to the current locally approved product information for indications, contraindications, warnings, preparation, storage, and administration.

10. XEOMIN and Neuronox: How Should Their Evidence Be Interpreted?

Neuronox is another botulinum toxin type A product with its own published clinical evidence, including randomized comparative research in glabellar lines.

The XEOMIN studies reviewed in BW-25, however, are not direct Neuronox-versus-XEOMIN trials. Their results should not be used to rank the two products by selecting response percentages from separate publications.

An evidence-based comparison should identify whether a study directly evaluated the products of interest and whether the populations, doses, endpoints, and assessment periods are comparable.

For product-specific discussion, Neuronox clinical trials should be reviewed independently rather than treated as interchangeable with the incobotulinumtoxinA evidence base.

11. Frequently Asked Questions

Has XEOMIN been studied in randomized clinical trials?

Yes. Published randomized trials have evaluated incobotulinumtoxinA in glabellar frown lines, including placebo-controlled and active-comparator designs. ［1–3］

Has XEOMIN been compared directly with BOTOX Cosmetic?

Yes. Randomized studies have compared incobotulinumtoxinA with onabotulinumtoxinA in defined glabellar-line protocols. ［2, 3］

Did the Kane study demonstrate equivalence?

The study reported equivalence for its prespecified primary endpoint within the defined margin at one month. The conclusion should not be generalized beyond the studied protocol. ［2］

Does equivalence mean XEOMIN and BOTOX are identical products?

No. Clinical equivalence at a specified endpoint does not establish identical formulation, labeling, potency assays, or outcomes in every indication.

Can XEOMIN units be universally substituted for units of another botulinum toxin product?

No. Dose comparisons must remain product- and protocol-specific.

Do these studies prove that XEOMIN is superior to other botulinum toxin products?

The principal active-comparator findings discussed here concern equivalence and non-inferiority. They should not be presented as universal superiority findings. ［2, 3］

12. Conclusion

XEOMIN/incobotulinumtoxinA has a randomized clinical evidence base for moderate-to-severe glabellar frown lines. The identified publications include placebo-controlled Phase III evidence, a direct 20-U equivalence trial against onabotulinumtoxinA, and an earlier active-comparator non-inferiority study. ［1–3］

These findings support efficacy within the studied protocols. Their interpretation must remain linked to the exact endpoint, dose, population, assessment time, and statistical framework.

For clinical communication, equivalence and non-inferiority should be described accurately, while product-specific labeling and potency units must be respected.

References

［1］ Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA in glabellar frown lines. Dermatologic Surgery. 2013;39:551–558. doi:10.1111/dsu.12100. Editorial note: Verify the complete author list and exact article title against the original publication before release.

［2］ Kane MAC, et al. A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery. 2015;41:1310–1319. doi:10.1097/DSS.0000000000000531.

［3］ Sattler G, et al. Noninferiority of incobotulinumtoxinA compared with onabotulinumtoxinA in glabellar frown lines. Dermatologic Surgery. 2010;36(Suppl 4):2146–2154. doi:10.1111/j.1524-4725.2010.01706.x.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.